Resolution Pharmaceuticals Inc.

Despite previously disappointing results, Genfit made good on earlier promises Nov. 16 when it announced that it is moving its NASH candidate into Phase III based on feedback from regulatory agencies.

The US FDA's alert about liver failure and death in patients taking AbbVie Inc.'s hepatitis C fixed-dose combination therapies Viekira Pak and Technivie is a significant setback for a company that alr

With the FDA set to make a decision any day on whether it will approve Apotex Corp.'s pegfilgrastim biosimilar, Amgen Inc. is seeking to block the product from entering the US market for at least six

An experimental gout drug from AstraZeneca plc unit Ardea Biosciences Inc., known as lesinurad, demonstrated only modest efficacy in clinical trials and has some concerning adverse cardiovascular (CV)